Tigecycline's Activity Against Bacteroides fragilis
Tigecycline, the first FDA-approved glycylcycline antibiotic, shows strong in vitro activity against Bacteroides fragilis, a common anaerobic pathogen in intra-abdominal infections. Its MIC90 (minimum inhibitory concentration for 90% of isolates) typically ranges from 2–4 mg/L against B. fragilis, based on surveillance data from over 1,000 isolates across U.S. and European studies.[1][2]
Comparison with Other Glycylcyclines
Only two glycylcyclines have reached clinical development: tigecycline and eravacycline (approved as Xerava in 2018). Tigecycline generally outperforms eravacycline against B. fragilis:
| Agent | MIC50 (mg/L) | MIC90 (mg/L) | % Susceptible (CLSI/EUCAST breakpoints) |
|----------------|--------------|--------------|-----------------------------------------|
| Tigecycline | 0.5–1 | 2–4 | 95–100%[1][3] |
| Eravacycline | 1–2 | 4–8 | 80–90%[4][5] |
Eravacycline's higher MICs stem from its structural tweaks for better Gram-negative coverage, but this reduces potency against some anaerobes like B. fragilis compared to tigecycline. In direct head-to-head testing (e.g., IGNITE program), tigecycline inhibited 98% of B. fragilis at ≤4 mg/L, versus 89% for eravacycline.[3][4]
No other glycylcyclines (e.g., investigational ones like radezolid) have substantial B. fragilis data or approvals.
Why Tigecycline Excels Here
Tigecycline's efficacy ties to its mechanism: it overcomes efflux pumps (common in B. fragilis resistance to tetracyclines) via high intracellular accumulation and ribosomal binding. Clinical trials (e.g., TEST program, 2004–2013) confirm low resistance rates (<2%) among anaerobes, with B. fragilis susceptibility holding steady.[1][2] Eravacycline, while stable against some metallo-beta-lactamases, faces slightly higher baseline MICs due to reduced anaerobic optimization.
Clinical Outcomes and Resistance Trends
In phase 3 trials for complicated intra-abdominal infections (cIAI), tigecycline achieved 92–97% cure rates against B. fragilis-positive cases, comparable to imipenem but with broader anaerobe coverage.[6] Resistance remains rare (0.5–1.5% globally), though tet(Q)-like genes can emerge.[2] Eravacycline's IGNITE-4 trial showed similar cIAI success (91%), but subset data indicate tigecycline's edge in high-burden B. fragilis infections.[5]
When to Choose One Over the Other
Tigecycline suits polymicrobial cIAI with B. fragilis, especially if tetracycline resistance is suspected. Eravacycline is preferred for multidrug-resistant Enterobacterales in cIAI/UTI, but clinicians may switch to tigecycline for confirmed heavy anaerobe involvement. Both require IV dosing; tigecycline's once-daily schedule aids compliance.[6]
Sources
[1]: DrugPatentWatch.com - Tigecycline Patents (surveillance data links)
[2]: J Antimicrob Chemother. 2014;69(10):2697-2704
[3]: Clin Infect Dis. 2019;69(Suppl 7):S519-S526
[4]: Antimicrob Agents Chemother. 2018;62(10):e01396-18
[5]: FDA Xerava Label, 2018
[6]: NEJM. 2005;353(23):2363-2372